Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention.

CONTEXT Bleeding complications with percutaneous coronary intervention (PCI) are associated with adverse patient outcomes. The association between the use of bleeding avoidance strategies and post-PCI bleeding as a function of a patient's preprocedural risk of bleeding is unknown. OBJECTIVE To describe the use of 2 bleeding avoidance strategies, vascular closure devices and bivalirudin, and associated post-PCI bleeding rates in a nationally representative PCI population. DESIGN, SETTING, AND PATIENTS Analysis of data from 1,522,935 patients undergoing PCI procedures performed at 955 US hospitals participating in the National Cardiovascular Data Registry (NCDR) CathPCI Registry from January 1, 2004, through September 30, 2008. MAIN OUTCOME MEASURE Periprocedural bleeding. RESULTS Bleeding occurred in 30,654 patients (2%). Manual compression, vascular closure devices, bivalirudin, or vascular closure devices plus bivalirudin were used in 35%, 24%, 23%, and 18% of patients, respectively. Bleeding events were reported in 2.8% of patients who received manual compression, compared with 2.1%, 1.6%, and 0.9% of patients receiving vascular closure devices, bivalirudin, and both strategies, respectively (P < .001). Bleeding rates differed by preprocedural risk assessed with the NCDR bleeding risk model (low risk, 0.72%; intermediate risk, 1.73%; high risk, 4.69%). In high-risk patients, use of both strategies was associated with lower bleeding rates (manual compression, 6.1%; vascular closure devices, 4.6%; bivalirudin, 3.8%; vascular closure devices plus bivalirudin, 2.3%; P < .001). This association persisted following adjustment using a propensity-matched and site-controlled model. Use of both strategies was used least often in high-risk patients (14.4% vs 21.0% in low-risk patients, P < .001). CONCLUSIONS In a large national PCI registry, vascular closure devices and bivalirudin were associated with significantly lower bleeding rates, particularly among patients at greatest risk for bleeding. However, these strategies were less often used among higher-risk patients.

[1]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[2]  Peter C. Austin,et al.  The Relative Ability of Different Propensity Score Methods to Balance Measured Covariates Between Treated and Untreated Subjects in Observational Studies , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  H. White,et al.  Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. , 2007, Journal of the American College of Cardiology.

[4]  David P Miller,et al.  Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. , 1996, The New England journal of medicine.

[5]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[6]  G. Imbens.  The Role of the Propensity Score in Estimating Dose-Response Functions , 1999 .

[7]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[8]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[9]  M. Müllner,et al.  Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. , 2004, JAMA.

[10]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[11]  Eric Peterson,et al.  Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. , 2006, Journal of the American College of Cardiology.

[12]  H V Anderson,et al.  The American College of Cardiology-National Cardiovascular Data Registry™ (ACC-NCDR™): building a national clinical data repository , 2001 .

[13]  P. Austin.  Goodness‐of‐fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score , 2008, Pharmacoepidemiology and drug safety.

[14]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[15]  T. Thom,et al.  American Heart Association Statistics Committee and Stroke Statistics Subcommittee : Heart disease and stroke statistical-2006 update : A report from the American Heart Association Statistics Committee and Stroke statistics subcommittee , 2006 .

[16]  A. Laupacis,et al.  Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies. , 2004, The American journal of medicine.

[17]  R. Bender,et al.  Calculating confidence intervals for the number needed to treat. , 2001, Controlled clinical trials.

[18]  P. Rosenbaum,et al.  Invited commentary: propensity scores. , 1999, American journal of epidemiology.

[19]  Deepak L. Bhatt,et al.  Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative , 2004 .

[20]  D. Rubin,et al.  Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score , 1985 .

[21]  G. Stone,et al.  Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. , 2008, Journal of the American College of Cardiology.

[22]  A. Yan,et al.  Understanding physicians' risk stratification of acute coronary syndromes: insights from the Canadian ACS 2 Registry. , 2009, Archives of internal medicine.

[23]  A. Laupacis,et al.  Risk-treatment mismatch in the pharmacotherapy of heart failure. , 2005, JAMA.

[24]  W. Weaver,et al.  The Influence of Clinical Risk Factors on the Use of Angiography and Revascularization After Acute Myocardial Infarction , 1995 .

[25]  K. Hammermeister,et al.  The American College of Cardiology National Database: Progress and challenges , 1997 .

[26]  Sunil V. Rao,et al.  Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry , 2009, Circulation. Cardiovascular interventions.

[27]  N. Weissman,et al.  Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. , 2003, The American journal of cardiology.

[28]  B. Strauss,et al.  Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. , 2005, American heart journal.

[29]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[30]  R. Moore,et al.  Using Numerical Results from Systematic Reviews in Clinical Practice , 1997, Annals of Internal Medicine.

[31]  E. Topol,et al.  Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. , 2007, The American journal of cardiology.

[32]  B. Armstrong,et al.  Ordinal regression models for epidemiologic data. , 1989, American journal of epidemiology.

[33]  R. Brindis,et al.  Risk of local adverse events following cardiac catheterization by hemostasis device use - phase II. , 2005, The Journal of invasive cardiology.

[34]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[35]  F. McAlister,et al.  Exploring the treatment-risk paradox in coronary disease. , 2007, Archives of internal medicine.

[36]  J. Spertus,et al.  Chronic total occlusion angioplasty in the United States. , 2009, JACC. Cardiovascular interventions.

[37]  E. Topol,et al.  Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). , 2004, The American journal of cardiology.

[38]  B. Gersh,et al.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial , 2009, The Lancet.

[39]  K. Eagle,et al.  Predictors of length of stay after coronary stenting. , 2001, American heart journal.

[40]  Deepak L. Bhatt,et al.  Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. , 2005, JAMA.

[41]  E. Topol,et al.  Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. , 2004, Journal of the American College of Cardiology.

[42]  A. Kastrati,et al.  Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. , 2008, Journal of the American College of Cardiology.

[43]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[44]  M. Matheny,et al.  A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices. , 2007, American heart journal.

[45]  G. Stone,et al.  Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial , 2010, Circulation. Cardiovascular interventions.

[46]  Patrice Degoulet,et al.  The number needed to treat: a clinically useful nomogram in its proper context , 1996, BMJ.

[47]  B. Lewis,et al.  General cardiology: abstractImportance of increasing age on the presentation and outcome of acute coronary syndromes in elderly patients , 2004 .

[48]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.